 Breast cancer is the second leading cause of death among women. Although early diagnosis and development of new treatments have improved their prognosis , many patients present innate or acquired resistance to current therapies. New therapeutic approaches are therefore warranted for the management of this disease. Extensive preclinical research has demonstrated that cannabinoids , the active ingredients of Cannabis sativa , trigger antitumor responses in different models of cancer. Most of these studies have been conducted with pure compounds , mainly Î”